title: Rituximab for eradicating inhibitors in people with acquired haemophilia A.
abstract: BACKGROUND
  Acquired haemophilia A is a rare bleeding disorder caused by the development of specific autoantibodies against coagulation factor VIII. Rituximab may be an alternative approach to the treatment of acquired haemophilia by eradicating FVIII autoantibodies.
  
  
  OBJECTIVE
  To assess and summarise the efficacy and adverse effects of rituximab for treating people with acquired haemophilia A.
  
  
  METHODS
  We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's trials registers, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and conference proceedings.Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's trials registers: 01 March 2016.
  
  
  METHODS
  Randomised and quasi-randomised controlled trials of rituximab for people with acquired hemophilia A, with no restrictions on gender, age or ethnicity.
  
  
  METHODS
  No trials matching the selection criteria were eligible for inclusion.
  
  
  RESULTS
  No trials matching the selection criteria were eligible for inclusion.
  
  
  CONCLUSIONS
  No randomised clinical trials of rituximab for acquired hemophilia A were found. Thus, based on the highest quality of evidence, we are not able to draw any conclusions or make any recommendations on rituximab for eradicating inhibitors in people with acquired haemophilia A. Given that undertaking randomised controlled trials in this field is a complex task, the authors suggest that, while planning such trials, clinicians treating the disease continue to base their choices on alternative, lower quality sources of evidence. The authors plan, for a future update of this review, to appraise and incorporate any randomised controlled trials, as well as other high-quality non-randomised studies.
authors.affiliation: Department of Hematology, General Hospital of Chengdu Military Region, 270#, Rongdu Da Dao, Chengdu, Sichuan, China, 610083.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zeng
authors.forename: Ruiqing
authors.initials: R
authors.lastname: Zhou
authors.forename: Xin
authors.initials: X
authors.lastname: Duan
authors.forename: Dan
authors.initials: D
authors.lastname: Long
mesh_terms: D001323:Autoantibodies; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D001323:Autoantibodies; D007155:Immunologic Factors; D000069283:Rituximab; D005169:Factor VIII